Repair Biotechnologies has developed REP-0004, an mRNA therapy delivered via lipid nanoparticles to the liver, designed to reduce excess intracellular free cholesterol and trigger systemic cholesterol drainage. The drug has received orphan drug designation and aims to enter clinical trials by mid-2027, with preclinical data suggesting rapid regression of atherosclerotic plaque and reversal of metabolic liver disease.
Key Points
- mRNA therapy targets liver hepatocytes to selectively degrade excess free cholesterol
- Liver reduction triggers feedback loop draining cholesterol from tissues systemwide
- Preclinical evidence shows rapid atherosclerotic plaque regression and liver disease reversal
Longevity Analysis
Free cholesterol accumulation in tissues is a pathological hallmark of aging and metabolic dysfunction. By restoring the liver's capacity to process and eliminate excess cholesterol—a function that degrades with age and metabolic stress—this approach addresses a root mechanism rather than treating downstream inflammation. The systemic effects arise from re-establishing proper homeostatic signaling, where the liver, once functional again, actively retrieves cholesterol from peripheral tissues. This represents a departure from symptom management toward restoration of impaired regulatory capacity, with implications for both cardiovascular disease reversal and metabolic health across multiple tissues.
Original published by LifeSpan.io, by Steve Hill.